Oct 2026
EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib.
Real-world evidence is provided of the molecular and clinical heterogeneity of EGFR exon 20-altered NSCLC and a possible survival difference according to loop location and a potentially favorable association between sunvozertinib exposure and OS among non-surgical patients are highlighted.
Jia-Hui Zhang, Yue-Chen Cui, Qing Ren et al.
· Clinical and Translational O... · 0 citations